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Abstract 
Osteosarcoma is the most frequent malignant primary bone tumor characterized by a high 
potency to form lung metastases which is the main cause of death. Unfortunately, conventional 
chemotherapies are not fully effective on osteosarcoma metastases. The progression of a primary 
tumor to metastasis requires multiple processes, which are neovascularization, proliferation, 
invasion, survival in the bloodstream, apoptosis resistance, arrest at a distant organ and 
outgrowth in secondary sites. Consequently, recent studies have revealed new insights into the 
molecular mechanisms of metastasis development. The understanding of the mechanism of 
molecular alterations can provide the identification of novel therapeutic targets and/or prognostic 
markers for osteosarcoma treatment to improve the clinical outcome. 
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Introduction 
Osteosarcoma (OS) most often occurs, during childhood and adolescence, in the 
metaphysis of long bones, including large growth plates with high proliferation activity and 
bone-turnover [1]. Historically, patients with primary OS have been treated with resectional 
surgery alone, resulting in poor prognosis. Clinical outcome of localized OS has improved with 
neoadjuvant chemotherapies, based on methotrexate, cisplatin, doxorubicin and ifosfamide 
treatments. The 5-year survival has indeed increased to around 60%. However, the 5-year 
survival of patients with OS metastasis still remains about 30% [2-7]. OS metastases appear most 
frequently in the lung [8] and is the main reason of death for patients with OS, because micro-
metastases are undetectable at initial diagnosis [9, 10]. Taken together, OS patients with 
metastases present further worse clinical results than those without metastases. Thus, more 
effective treatments and/or a more personalized therapy (i.e. treatment according specific gene or 
protein profile expression) are needed for patients with OS associated with pulmonary 
metastases. 
The establishment of cancer metastasis involves several complex steps: intravasation, 
survival in the circulation, arrest at a distant organ, extravasation and growth in secondary sites 
(Fig. 1). Molecular alterations of these steps have been practically analyzed. The understanding 
of metastasis mechanism might allow us to find new molecular targets for improvement of the 
patients‟ survival. This review describes the molecular factors associated with OS development 
and summarizes the main molecular alterations involved in this bone disease, especially in 
metastatic OS, which strongly contribute to the development of new therapeutic approaches. 
 
Neovascularization is a key parameter in osteosarcoma growth 
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Nutriments and oxygen required for the metabolism of normal and tumor cells are delivered by 
blood vessels. In malignants pathologies, neoformation of blood vessels allows growth, invasion 
and metastatic spread of cancer cells. [11, 12]. The process of neovascularization is generally 
regulated by a balance between angiogenic inducers and inhibitors. The shift in favor of 
angiogenic inducers, known as the “angiogenic switch”, promotes the formation of a new blood 
supply enhancing tumor growth and metastasis. In an oncologic context, neovascularization is 
induced by the tumor environment such as hypoxia, acidosis or inflammation. In these 
conditions, both tumor cells and host endothelial cells can increase the expression of pro-
angiogenic: vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), 
basic fibroblast growth factor (bFGF) and transforming growth factor (TGF-β) [13, 14] [13, 
14][15-17]. Tumor cells also secrete proteolytic enzymes such as matrix metalloproteinases 
(MMPs), which degrade basement membrane and extracellular matrix (ECM) promoting cell 
dissemination [18, 19]. MMP-9 is indeed highly related to the angiogenic switch because it can 
activate pro-angiogenic factors [20, 21]. Several studies have demonstrated that VEGF or TGF-β 
expression is associated with an increase of tumor vascularity, invasion and poor prognosis in 
OS [22-24]. It has been shown that high serum-VEGF levels in OS correlate with tumor 
progression, metastasis and poor prognosis [25, 26]. However, the relationship between an 
increase of tumor vascularity and a poor prognosis is controversial in OS [27-29].  
The well-known angiogenic inhibitors are angiostatin and endostatin. Angiostatin is a 
cleavage product of plasminogen [30], whereas endostatin is the carboxyl-terminal fragment of 
collagen XVIII [31]. They inhibit endothelial cell proliferation and migration [32]. The resulting 
anti-angiogenic activity has been demonstrated in various tumor models in vivo [33-38]. Based 
on these (pre)clinical results, clinical trials are currently running to evaluate the effect of human-
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recombinant endostatin. Although showed a well tolerability, and safety in patients with 
malignant solid tumors it induces a minor anti-tumor effect, effect not related to the vascular 
changes [39-41]. Inhibition of neovascularization should suppress tumor growth despite tumor 
cell heterogeneity because blood supply is necessary for all tumors to survive. Furthermore, the 
available data from animal models and phase I and II clinical trials of angiostatin and endostatin 
have shown that these agents are well-tolerated at therapeutic doses: 15-600 mg/m
2
/day added to 
those patients, although the use of anti-angiogenic therapy has raised the debate about 
interference with normal physiological processes such as wound healing and tissue repair [31, 
39-43].  
 
Migration and invasion: two potential therapeutic targets 
Tumor migration and invasion through the ECM play are critical in metastasic dissemination [15, 
16]. In OS, degradation of the ECM, which leads to migration, invasion and metastasis, releases 
MMPs (MMP-2 and MMP-9, especially) and m-calpain [44-46]. In addition, the Wnt/β-catenin, 
Src-kinase and Notch signaling pathways are also involved in migration and invasion [47-55]. 
MMPs are a family of zinc endopeptidases consisting of at least 20 different members 
and regulate different cellular metabolic processes [56, 57]. They induce a variety of biological 
effects including growth, morphogenesis, apoptosis, tissue destruction and cancer formation [58, 
59]. Recently, bisphosphonates have been shown to down-regulate MMPs expression and reduce 
the invasive potency of OS cells [60-64]. Disulfiram is also able to control the invasion and 
metastasis in human OS cells through the MMP-2 and MMP-9 inhibition [65]. Both of m-calpain 
expression and MMP-2 secretion are inhibited by a siRNA targeting m-calpain in SAOS-2 cells 
[46]. m-calpain is also essential in the invasion and human OS metastasis [46]. These agents 
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related to proteases represent new therapeutic targets and approaches to decrease the OS 
migration and invasion.  
Wnt signaling pathway coordinates osteoblast proliferation and differentiation [66]. 
Disruptions in various components of the Wnt pathway result in disordered bone development 
and homeostasis [67]. The β-catenin dependent Wnt signaling pathway is regulated by secreted 
Wnt antagonists divided into two groups. Wnt inhibitory factor 1 (WIF-1) and the secreted 
frizzled-related protein family directly bind to Wnt ligands while the dickkopf families and 
sclerostin are blocking Wnt receptors trough the endocytosis of low-density lipoprotein receptor-
related protein 5/6 co-receptors [68-71]. This Wnt binding leads to the activation of disheveled, 
which in turn, releases β-catenin from the axin-adenomatous polyposis coli-glycogen synthase 
kinase-3β complex, causing stabilization and accumulation of β-catenin in the cytoplasm. After 
its translocation to the nucleus, β-catenin binds to the T-cell factor/lymphocyte enhancer factor 
family of transcription factors and promotes downstream target oncogenes such as c-myc, cyclin 
D, survivin and MMPs. These mechanisms are involved in proliferation, invasion and metastasis 
in various human cancers [72-75]. OS frequently express high levels of cytoplasmic and/or 
nuclear β-catenin [76], which is also associated with metastasis [77, 78]. These findings suggest 
that aberrant Wnt activation is crucial in multiple cancers, including OS [79-81]. A preclinical 
study has demonstrated that the inhibition of Wnt/β-catenin pathway induced lower levels of 
nuclear β-catenin, resulting in down-regulation of the β-catenin-targeted genes such as MMP-9, 
cyclin-D, c-myc and survivin [82]. Several reports have demonstrated that WIF-1 silencing due 
to hypermethylation results in Wnt signaling activation in a variety of cancer. WIF-1 can inhibit 
the cell-growth of those cancer cells [79, 80, 83-86]. The down-regulation of WIF-1 expression 
plays a role in OS progression. Re-expression of WIF-1 also suppressed Wnt signaling pathway, 
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resulting in the tumor growth and lung metastasis in vivo in OS mouse models [50]. These results 
indicate that WIF-1 can be a therapeutic agent against OS metastasis. However, the function of 
Wnt antagonists including WIF-1 is still unclear and further investigations are needed. 
Notch signaling regulates development of many tissues and cell types through diverse 
effects on cell fate decision, stem cell renewal, differentiation, survival and proliferation [87]. 
Notch signaling is one of several evolutionarily conserved signaling pathways in the 
development of multi-cellular organisms. Its temporal-spatial expression effects can specify 
diverse cellular events, including proliferation, differentiation, apoptosis and stem cell 
maintenance. In mammals, there are four Notch receptors: Notch1-4, and eleven ligands [88]. 
The first targets of Notch are two basic helix-loop-helix transcriptional repressor families: the 
Hairy/enhancer-of-split (Hes) and the Hes with YRWP motif families [89]. Notch has been 
considered as a promoter of invasion in OS. The Notch receptor 1, 2 and Hes1 genes induced by 
Notch increase in highly metastatic OS. In human OS, the Hes1 gene was inversely associated 
with the survival rate [52-55]. In a preclinical setting, the OS cell invasion was reduced by an 
inhibition of the Notch signaling pathway whereas the cell proliferation was not blocked. The 
Notch-inhibited cells were less able to induce lung metastases in an orthotopic mouse than the 
negative controls. However, the mechanism in the inhibition of the Notch pathway and the 
down-regulation of invasion resulted from Hes1 remains not clear [53, 55]. 
Src is a non-receptor tyrosine kinase and encoded by the c-Src as a proto-oncogene. Src 
kinase activity is regulated by several receptor tyrosine kinases (RTKs) such as epidermal 
growth factor (EGF) RTK, PDGF-RTK and integrin receptors [90-92]. Src family kinases are 
critical in the metastatic dissemination, such as cell proliferation, adhesion, invasion, survival 
and angiogenesis. Either overexpression or activation of c-Src has been shown to occur in cancer 
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development [49]. Src, involved in tumor metastasis widely, could be a novel therapeutic target 
in OS metastasis. Dasatinib, known as a Src kinase inhibitor, suppresses Bcr-Abl tyrosine kinase. 
The effect and safety of dasatinib have been established as therapeutic agent for imatinib-
resistant chronic myelogenous leukemia in early-phase clinical trials. Also, several studies have 
shown that the dasatinib acts against Bcr-Abl-positive leukemic cell lines as well as other 
malignancies. The c-Src-mediated signaling pathways, related to tumor proliferation, adhesion, 
or migration, have been shown in various malignancies such as prostate cancer, lung cancer and 
sarcoma [93-95]. In preclinical studies, dasatinib suppressed tumor migration and invasion with 
inhibition of the Src kinase activity and its downstream signaling in OS cell lines in vitro [48, 
96]. On the other hand, dasatinib had no effect on pulmonary metastases in vivo [48]. At present, 
the other specific Src kinase inhibitor, called saracatinib, is under investigation in phase II 
clinical trial of OS lung metastases (clinicaltrials.gov/ct2/show/NCT00752206). 
 
Apoptosis resistance and OS progression 
Apoptosis is involved in cell-survival in cancer metastasis through the all stages via two 
pathways. The first one is regulated by a death receptor bound to Fas or tumor-necrosis factor 
(TNF) family member, death-inducing signaling complex, and caspase-8. The second one is 
associated with p53, Bcl2 family member, cytochrome-c and caspase-9. When caspase-8 or -9 is 
activated, caspases of the downstream can be cleaved inducing cell death.  Fas and its ligand 
(FasL) belong to the TNF death receptor superfamily and regulate tumorigenesis in a variety of 
primary malignancies and metastases [97-99]. Fas/FasL complex, constitutively expressed in 
lung tissue, enhances the Fas-apoptosis pathway and leads to cell death [100, 101]. Fas receptor 
has been well-known as a death receptor mediated apoptosis in a variety of tumor cells. Recent 
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studies have revealed that Fas is also pro-apoptotic related to tumor proliferation, differentiation 
and migration [102-104]. Thus, apoptosis resistance is crucial for establishment of tumor 
metastasis; it is implicated in treatment-resistance with cancer metastasis [105]. Fas expression is 
often decreased in OS lung metastasis, whereas it is highly expressed in the primary tumors [100, 
101, 106]. Furthermore, Fas-negative expressions correlate with tumor development and poor 
prognosis [100, 101, 107-109]. Inhibition of Fas signaling and/or the loss of FasL can develop 
the proliferation of Fas-positive OS cells in the lungs and can promote the growth of lung 
metastases in OS models in vivo [107].  
Interleukin (IL)-12 increased the expressions of Fas receptor in OS lung metastasis 
through stimulation of the Fas promoter activity. In turn, the metastatic cells acquired the 
susceptibility to FasL in relation to Fas-induced apoptosis in the lung microenvironment [110]. 
In vivo, combination therapy of IL-12 with ifosfamide induces FasL expression, increasing the 
therapeutic efficacy via the Fas/FasL pathway [111]. Muramyl tripeptide phosphatidyl 
ethanolamine (MTP-PE) induces IL-12 production in OS patients through activation of 
macrophages [1, 112]. MTP-PE also up-regulates Fas expression when exogenous IL-12 is 
administered to the patients [106]. The combination of MTP-PE with ifosfamide induces IL-12 
and FasL respectively, consequently the clinical outcome of the patients treated can be improved 
through the activation, of tumor apoptosis [106]. These results suggest that Fas death receptor 
pathway may enhance the efficacy of chemotherapy in OS. 
IL-18,which is an interferon-γ-inducing factor [113], affects an anti-tumor effect via the 
activation of natural killer (NK) cells or cytotoxic T-cells [113, 114], inhibition of angiogenesis 
[115] and induction of FasL on Fas-positive tumor cells [116]. IL-18 has been shown to inhibit 
metastasis in OS cells through the activation of T-cells and NK-cells and induction of the FasL 
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expression [117]. In addition, the combination of ifosfamide with IL-18 suppresses the 
development OS lung metastasis [118]. Taken together, Fas death receptor pathway is essential 
in the establishment of OS lung metastasis, and it may be a novel therapeutic target. However, 
the molecular mechanism of the loss of Fas-mediated apoptosis in OS metastases is unknown. 
 
 Survival in the blood circulation: Anoikis resistance 
Cancer metastases require the anoikis-resisted cells to survive in the circulation.  Anoikis, Greek 
for „„homelessness‟‟, regulates cell homeostasis in tissues. Normal epithelial cells become 
apoptotic when exposed to anchorage-independent environments [119, 120]. In turn, once tumor 
cells have entered into the bloodstream to disseminate distantly, the cell-cell adhesions or ECM 
attachments are lost, which results in the specific apoptosis called anoikis [121]. Therefore, 
metastatic cells need to acquire the resistance to anoikis to survive during dissemination and 
colonization of secondary distant sites in the circulation. 
Acquisition of anoikis resistance  has been described in non-epithelial malignancies such 
as OS [122]. Many studies demonstrated the survival mechanism of cancer cells in the evasion of 
anoikis with various means such as Src/PI3K/Akt pathway, focal adhesion kinase, or Bcl-2 [123, 
124]. Several studies have shown that β4 integrin expression is involved in cancer progression 
[125-127]. Also, the β4 integrin expression is implicated in the survival of OS cells in the 
circulation, because knockdown of β4 integrin suppressed the cell-proliferation under anchorage-
independent sites in OS cells [128]. In addition, the knockdown of β4 integrin in a mouse model 
inhibited lung metastases, and β4 integrin-ezrin interaction appears to be essential for β4 integrin 
expression. However, the relation between ezrin and β4 integrin is still unknown [128]. Cell-cell 
adhesions can activate integrin signaling in anchorage-independent conditions and integrin 
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expression patterns may contribute to the resistance to anoikis [129].  
Switch from αVβ5 to αVβ6 integrin may suppress anoikis in squamous cell carcinoma cells 
through the activation of PI3K/Akt signaling pathway [130]. The PI3K/Akt pathway, which 
depends on Src kinase activation, is important for human OS cells to avoid anoikis [47]. Src has 
another role related to anoikis resistance with caveolin-1 in OS cells. Caveolin-1 is the major 
protein component of caveolae [131], which regulates several intracellular signaling pathways 
[132]. Caveolin-1 is highly expressed in osteoblasts [133] and its overexpression in OS cells 
inhibited anchorage-independent growth, invasion, and migration by blocking c-Src and c-Met 
tyrosine kinases in vitro [134]. In addition, Caveolin-1 overexpression suppressed the OS 
metastasis in vivo [134].  
 
Arrest and extravasation: final step of cell migration 
The mechanism of migration arrest of metastatic cells is controversial. Metastatic tumor cells are 
generally thought to be trapped in the microcirculation because their size is larger than the size of 
normal cells [135]. When the tumor cells in the bloodstream are trapped, micro-embolisms are 
structured, and the interaction with the local microenvironment begins consequently. 
Interestingly, cancer cells have the tendency to prefer a specific target organ in metastasis 
processes: Over 80% of all metastases in OS occur in the lungs [136]. This result suggests that 
circulating tumor cells can select their optimal sites to survive and grow via interactions with 
distinct molecules expressed on the endothelial cells in the distant organs [16]. In the circulation, 
cell colonization in the distant organs is mediated through the secretion of chemokines and 
proteinases, involved in extravasations [15, 16]. Recently, chemokines are regarded as important 
factors to control a site-specificity of cancer metastasis including OS-lung relation [137-140]. C-
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X-C-motif chemokine receptor 4 (CXCR4) and its ligand C-X-C-motif chemokine ligand 12 
(CXCL12) have been shown to regulate an organ-specific metastasis by the formation of 
chemotactic gradients in several cancer [141-143]. Binding of CXCR4 to CXCL12 allows 
adhesion and extravasation of OS cells in pulmonary metastasis [138, 139, 144, 145]. These 
results suggest that abundant expressions of CXCL12 in the lung may be involved in the high 
frequency of pulmonary metastases in OS. Highly CXCR4 expressions in OS-patient samples 
adversely correlated to event-free, overall, and, metastasis-free survival [138]. These data 
suggest that CXCR4 could be useful as a prognostic factor in OS metastasis.  
CXCR3, another chemokine receptor, has been identified in a variety of malignancies 
including OS [138, 146-148]. Its ligands, CXCL9, 10 and 11, are expressed in lungs. The 
inhibition of CXCR3 chemokine pathway down-regulates the growth of OS lung metastasis. 
Recent study has demonstrated that CXCR3 inhibitor decreased the proliferation, survival and 
invasion of the tumor cells in an animal model of OS lung metastasis. In other words, the 
interaction between CXCR3 and its ligands can directly enhance the invasion, survival and 
proliferation of tumor cells in the metastatic organ. This result suggests that targeting CXCR3 
can specifically inhibit OS lung metastasis [144]. 
 
Adhesion step in the metastatic process 
Establishment at a distant organ requires that the metastatic cell connects to its new environment 
and re-establishes cell-cell adhesions. Ezrin is a membrane-cytoskeleton linker protein that acts 
as membrane organizers and linkers between plasma membrane and cytoskeleton [149] 
controlling. cell-microenvironment and cell-cell interactions. In addition, ezrin associates with 
several signaling transductions, such as Rho and PI3K/Akt pathways [150, 151]. Recently, high 
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level expression of ezrin protein is correlated to metastasis in several cancers [152-154] as well 
as OS [155, 156]. High expression of ezrin is associated with pulmonary metastasis in animal 
models [155, 157], and with poor outcome in pediatric OS patients [155]. Phosphorylated ezrin 
was shown to express at just early phase in lung metastasis [155] whereas  it was dynamically 
expressed at both the early and late time point [156].   
Sorafenib is a multipotent drug, and several molecular targets of sorafenib such as Raf 
kinases are implicated in OS development [158, 159]. Recent preclinical study has reported that 
sorafenib suppressed the development of lung metastases via down-regulation of ezrin-activated 
Mitogen-activated protein kinase (MAPK)/Akt signaling [160]. In addition, sorafenib could 
induce apoptosis through a decrease of expression of the anti-apoptotic Bcl-2 family [160]. 
These data suggest sorafenib may be a novel potential therapeutic option in patients with OS 
metastasis. 
 
Main signaling pathways involved in proliferation of metastatic OS 
OS pathogenesis is clearly related with bone growth during adolescence, suggesting a potential 
relationship with higher expression of hormone levels [161, 162]. Thus, several studies have 
suggested that molecular alterations in the GH/IGF-I signaling pathways could lead to OS 
development in vitro and in vivo [163, 164]. OS cells show both IGF-I and IGF-I receptor 
expression and highly-response to IGF-I in vitro [164]. Serum IGF-I levels in mice with 
hypophysectomy are significantly down-regulated, which is decreasing tumor growth and 
development of metastasis [165]. 
A phase I trial in patients with metastatic and/or recurrent OS was performed with 
somatostatin analog (OncoLar®) to reduce serum IGF-I [166]. In this trial, OncoLar ® treatment 
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in 21 OS patients resulted in a 46% decrease in serum IGF-I levels without toxicity. In a 
preclinical study conducted on dogs with naturally occurring OS, OncoLar® [167] reduced 
serum IGF-I levels were by approximately 43% without toxicity However, no difference in 
primary tumor necrosis, apoptosis or survival was observed in dogs treated with a combination 
of OncoLar® and chemotherapy in comparison with just chemotherapy. These observations 
indicate that the extent or duration of serum IGF-I suppression induced by OncoLar® was not 
enough to improve a clinical outcome. Also, IGF-I receptor (IGF-IR) axis is implicated in OS 
development; inhibition of IGF-IR could inhibit tumor growth, activate apoptosis and up-
regulate the chemo-sensitivity and radio-sensitivity in OS cells [168, 169]. 
Recently, human monoclonal antibodies targeting the IGF-IR were tested in both 
preclinical and clinical studies. Inhibition of IGF-IR with some monoclonal antibodies enhances 
the anti-tumor effects in several OS xenograft models [170, 171]. More recently, a clinical study 
has demonstrated that high IGF-IR expression is a poor prognostic factor for OS patients leading 
to OS development and metastasis [172]. Thus, IGF-IR targeting therapy can be a novel strategy 
for the treatment of OS associated with metastasis. 
 
 Dormancy 
Unfortunately, tumor metastasis occasionally occurs for patients with malignancies a long time 
after the success of primary therapy [173, 174]. This latency period is generally the result of 
tumor dormancy, which is frequently asymptomatic and clinically undetectable for months or 
years until relapse. Once tumor cells are settled in a secondary site, they can grow, die by 
apoptosis or remain dormant. Two ways of tumor dormancy have been described, i) tumor mass 
dormancy (dormant micro-metastases) and ii) cellular dormancy [174-176]. In dormant micro-
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metastases, tumor cells generally divide but the growth is limited. Cellular dormancy (dormant 
single tumor cell) can occur when tumor cells enter in a quiescence state and do not divide any 
more. Tumor cells in dormancy are usually resistant to conventional drug because current 
treatments target cells in division. However, the mechanisms allowing dormant tumor cells to 
survive to conventional chemotherapies and then resume the tumor outgrowth remain unknown.  
Dormant micro-metastases are thought to be present under a balance between cell 
proliferation and apoptosis [176, 177]. Dormant state of micro-metastases is involved in lack of 
nutrition and oxygen from vasculature in relation to angiogenic switch and/or the adaptive 
immune system [178-182]. Endothelial cells in the microenvironment can enhance dormant 
tumor cells via cell-to-cell interactions and induction of angiogenesis [180]. The ECM also plays 
an important role in activation of dormant cells. When tumor cells fail to adhere to the ECM, 
they may enter in dormancy. It has been postulated that micro-metastases fail to properly connect 
to the ECM and survive in the dormant state because they are deprived of growth factors and 
angiogenic signaling. Adhesion to the ECM could induce tumor cells to switch a dormancy state 
to a proliferation state via integrin signaling [181]. On the other hand, both tumor cells and host 
stromal cells modulate the microenvironment such as ECM and vascular wall. Those 
mechanisms may regulate the maintenance in dormancy or the activation metastatic growth for a 
single tumor cell or micro-metastases respectively (Fig. 2) [17, 181]. 
In vivo molecular mechanisms of a variety of cancers including OS in dormant state have 
been assessed with genome transcriptional analysis [181]. This study suggests that anti-
angiogenic proteins such as angiomotin, which has been shown to suppress tumor growth and 
keep dormancy of tumor metastases [179], are up-regulated during dormancy. Thus, the tumor 
proliferation and invasion are inhibited under pre-angiogenic state. Also, tumor cells in 
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proliferation state increased the key cancer pathways such as EGF receptor-1, IGF-IR, and PI3K.  
The mechanism of regulating tumor dormancy is unknown in OS. However, if it is possible to 
induce and/or keep in a dormant state or to induce cell death in residual dormant cells by 
targeting their survival and drug resistance mechanisms, the treatment for the patients with OS 
may be further improved. 
 
Conclusion 
OS associated with metastases still have poor clinical outcome, and conventional therapies are 
not fully effective. In addition, clinical output of novel available chemotherapeutic approaches is 
still unclear. Recent studies have disclosed new insights into the molecular mechanisms of 
metastasis as above mentioned. However, much more unknown questions remain; determinant 
factors of selective colonization in different organs, the mechanisms of tumor dormancy and the 
mechanisms of metastasis suppressors etc. Thus, future research critically needs to be directed 
towards identifying the molecular alterations in OS microenvironments. 
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Figure legends 
Figure 1: The main steps of the tumor metastatic process.  
Tumor cells proliferate at the primary site and neovascularization is induced by tumor 
environment such as hypoxia. In turn, they migrate and invade into the bloodstream. These 
tumor cells in the circulation need to survive against anoikis to arrest in a distant organ. 
Metastatic colonization at the secondary site involves the interactions between tumor cells and 
the microenvironment.  
 
Figure 2: Tumor metastasis dormancy is associated with the risk of recurrence of OS and 
late development of lung metastases 
Tumor dormancy is thought to consist of tumor mass dormancy (dormant micrometastases) and 
cellular dormancy. In tumor mass dormancy (dormant micrometastases), tumor cells generally 
divide but not in cellular dormancy. The tumor growth is strictly limited by the lack of blood 
supply or immune system. Dormant state of micrometastases is involved in angiogenic switch 
and/or the adaptive immune system. Dormancy therapy could contribute to improve the 
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treatment of patients with cancer.  
 
 
 
 
 
 
